Our Passion for IPOs
News & Views
Largest Global IPOs
Largest US IPOs
Largest US IPOs YTD
Largest US Internet IPOs
Top First Day Returns
US IPO Stats
IPO Average Age
IPO Industry Breakdown
Offer Price Discounts
Global IPO Stats
IPOs by Region
IPO Industry Breakdown
Register for Updates
Press Contact Form
Follow us on g+
Like us on Facebook
Follow us on LinkedIn
Free iPhone App
Free Android App
IPO News Feed
IPO News Archive
New Ways to Invest in IPOs
The US IPO Pipeline Update: Filings pick up in mid-May
Analyst IPO Blog
Only three companies set terms since last Monday, and none were technology or health care companies (
which account for over half of IPOs this year
). In terms of IPOs, this year has seen the busiest January, February, March and April in at least ten years, but May should fail to achieve more
pricings than last year
. Along with a recent correction in the IPO market (as seen in the Renaissance Capital IPO ETF, symbol "
"), IPO activity typically slows down before a holiday week.
Parsley Energy (
), a fast-growing oil and gas E&P operating in the West Texas Permian Basin, is
on the calendar
to begin trading on Friday. The IPO should raise about $600 million for the company and $123 million for selling insiders, which include primary backer Natural Gas Partners and executives. Year to date, Parsley’s top three closest peers have traded up between 32% and 42%. SunEdison Semiconductor (
), which makes silicon wafers for semiconductors used in phones and tablets, is a spinoff of solar energy company SunEdison (NYSE:SUNE). Its largest customer, Samsung, is investing $100 million in a concurrent private placement, but the IPO could face headwinds due to poor peer trading (SUMCO is down 8% over the last month).
IPO terms filings (May 12, 2014 to May 20, 2014)
Deal Size ($mm)
LTM Sales ($mm)
Parsley Energy (
Oil and gas E&P in the Permian Basin
SunEdison Semiconductor (
Silicon wafers for semiconductors; spinoff of SunEdison
Heritage Insurance Holdings (
Florida-based residential insurance
Citizens Financial and GoPro join the IPO pipeline
14 companies filed for IPOs during the past two weeks, bringing May's current number up to 25 and the total US IPO pipeline to 123 companies looking to raise $49 billion. By far the largest company to submit an initial filing in the past two weeks was Citizens Financial Group (
), the commercial banking arm of RBS. It is the 13th largest retail bank in the US, with about 1,370 offices and $4.7 billion in revenue//$122 billion in assets. We estimate that Citizens, the 13th largest retail bank in the US, could raise as much as $3 billion, ahead of the year's two largest IPOs - Santander Consumer USA (
) and Ally Financial (
Two new filers are consumer electronics companies, which have been absent from the IPO market since Skullcandy's public offering in 2011. GoPro, which makes wearable HD action cameras, filed for an IPO on Monday. The listed deal size is $100 million, but its strong cash flow (2013 adjusted EBITDA of $133 million) and fast growth (148% 3-year sales CAGR) suggest it could plan to raise more. Victory Electronic Cigarettes (
), which currently trades on the OTC markets, filed for a $150 million uplisting to the NASDAQ. The company has acquired several domestic and international brands of e-cigarettes, which continue to grow rapidly but more recently have come under regulatory scrutiny in US markets.
Good Technology's $100 million IPO filing comes just one month after close competitor MobileIron (
) filed plans to raise $100 million. Another competitor, AirWatch, was acquired by VMware in January for $1.5 billion. These mobile device management companies provide enterprises with tools aimed at securing corporate data on employees' mobile devices as businesses increasingly move work onto mobile. Enterprise software IPOs had recently stalled amid a technology selloff, but
Zendesk's successful IPO
last Thursday and its positive aftermarket trading may encourage others.
Four biotechs have filed for IPOs since last Monday, signaling that the biotech window could reopen soon as the backlog builds. With nine filings so far, May could be one of the busiest months for biotech filings if the pace continues. Seeking to raise $115 million, Kite Pharma (
) is the largest IPO of the four. Its filing arrives as cancer immunotherapy drugs are explored for more types of tumors, based on developments from Bristol-Myers Squibb, Merck and Roche. ZS Pharma (
), which develops one of the two most promising treatments for hyperkalemia, filed for a $100 million IPO last week. Relypsa (
), its a direct competitor and November 2013 IPO, is now trading at half of its March's peaks, but still trades 101% above its IPO price. A non-biotech health care company Parnell Pharmaceuticals Holdings (
) is notable for its medicinal products primarily focused on companion animals and follows the IPO of Phibro Animal Health (
, +23% from IPO) in April.
IPO initial filings (May 12, 2014 to May 20, 2014)
Deal Size ($mm)
LTM Sales ($mm)
Citizens Financial Group (
US banking arm of RBS
Victory Electronic Cigarettes (
Owns a portfolio of electronic cigarettes
Kite Pharma (
Biotech: utilizes immune system to fight cancer
Leading maker of wearable action cameras
Good Technology (
Mobile device management for enterprises
Amphastar Pharmaceuticals (
Drugs include generic version Sanofi's Lovenox
ZS Pharma (
Biotech: treatments for hyperkalemia
Biotech: small molecule treatments for GI diseases
Marinus Pharmaceuticals (
Biotech: add-on epilepsy therapy
Parnell Pharmaceuticals Holdings (
Health care products for companion animals
NextEra Energy Partners, LP (
Clean energy LP carved out of NextEra Energy
Investar Holding (
Louisiana commercial bank with 10 offices
U.S. Rare Earths (
Exploratory rare earth elements mining
MOKO Social Media (
Custom mobile social media platforms
Keywords / Tickers:
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included:
IPO investment firm Renaissance Capital (www.renaissancecapital.com)
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Net Asset Value (NAV)
of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding.
is current value at which an asset or service can be bought or sold.
is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
The S&P 500® Index (SPX)
is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE. The S&P 500 index components are determined by S&P Dow Jones Indices.
Investments in the
Renaissance IPO ETF, symbol "IPO"
(the “ETF”) and the
Global IPO Fund, symbol "IPOSX"
(the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETF and the Mutual Fund (the “Funds”) invest in companies that have recently completed their initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. The Funds may also be subject to information technology risk and small and mid-capitalization company risk due to a greater number of IPOs in these sectors. The Funds may hold securities in the form of Depository Receipts, REITs, Master Limited Partnerships (MLPs) which have greater risks than common shares. The strategy has high portfolio turnover and securities lending risks. ETF returns may not match the return of the respective index. The ETF is classified as a non-diversified investment company and is subject to concentration risk.
Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with information about the Funds, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETF, 1-866-486-6645.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the
Renaissance IPO ETF (symbol: IPO)
Global IPO Fund (symbol: IPOSX)
, may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2014 Renaissance Capital LLC. All rights reserved.